Drugs that contain Teduglutide Recombinant

1. Drug name - GATTEX KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056886

(Pediatric)

NPS PHARMS INC GLP-2 formulations Mar, 2023

(5 months from now)

US9545435 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9993528 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968658 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9572867 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9592273 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9539310 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9974835 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9555079 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9987334 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9060992 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9981016 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968656 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9987335 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9592274 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9974837 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9981014 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US7847061 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9545434 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968655 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9545434

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9555079

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US7847061

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9060992

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9592274

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9592273

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9572867

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9987335

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9993528

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9981016

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968658

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9974835

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9974837

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968656

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968655

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9987334

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9981014

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9539310

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9545435

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
5MG/VIAL POWDER;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.